HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Pepsinogen C

Subscribe to New Research on Pepsinogen C
Share|Follow on Twitter
This is one of the 2 related pepsinogen systems in humans. It is found in prostate and seminal fluid whereas PEPSINOGEN A is not.
Also Known As:
Pepsinogen II; Progastricsin
Networked: 139 relevant articles (6 outcomes, 16 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Vizoso, F: 7 articles (04/2002 - 01/2000)
2. Yuan, Yuan: 6 articles (08/2009 - 01/2003)
3. González, L O: 6 articles (07/2004 - 01/2000)
4. Merino, A M: 5 articles (04/2002 - 01/2000)
5. Quintela, I: 5 articles (10/2001 - 04/2000)
6. Rodríguez, J C: 4 articles (04/2002 - 01/2000)
7. Zhang, Ye: 3 articles (08/2009 - 11/2006)
8. Chen, Wei: 3 articles (08/2009 - 11/2006)
9. Lopes, Carlos: 3 articles (06/2008 - 09/2004)
10. Fernández, R: 3 articles (01/2001 - 04/2000)

Related Diseases

1. Gastritis
03/01/1995 - "In contrast, there was no significant correlation between serum pepsinogen C and any of the gastritis scores. "
11/01/1993 - "In the 22 patients in whom therapy resulted in dramatic decrease in gastritis scores and in clearance of the bacteria, there was a highly significant (P = 0.0001) fall in mean serum pepsinogen II from 13.3 +/- 0.8 to 7.9 +/- 0.7 micrograms/liter, and a less pronounced fall in pepsinogen I from 89.0 +/- 5.9 to 78.5 +/- 0.4 micrograms/liter (P = 0.01). "
11/01/1995 - "In 48 successfully eradicated cases, there was a significant decrease in gastritis score, and was a significant fall in serum pepsinogen II (PG II) level, and was a significant increase in pepsinogen I/II ratio (PG I/II ratio). "
01/01/1982 - "The predominance of pepsinogen I in the serum of healthy control subjects suggests that either the gastric chief cell normally releases more pepsinogen I than pepsinogen II into the circulation or that pepsinogen I has longer metabolic clearance rate than pepsinogen II. The marked decrease in serum pepsinogen I in patients with pernicious anemia is best explained by a loss of gastric chief cells due to severe atropic gastritis of te fundic glands. "
01/01/2003 - "The serum pepsinogen levels of stomach cancer patients, especially pepsinogen I and the pepsinogen I/pepsinogen II ratio were significantly lower than those of normal controls and correlated well with the extent of chronic gastritis associated with the cancerous stomach. "
Order ALL the reference details at left...
2. Infection
3. Inflammation
4. Adenocarcinoma
5. Pernicious Anemia
08/01/1989 - "In contrast, pepsinogen C was predominant in the serum of 26 patients with pernicious anemia. "
08/01/1989 - "In 27 patients with total gastrectomy the levels of both pepsinogen A (means = 2.5 ng/ml, range 2.2-2.8 ng/ml) and pepsinogen C (means = 1.9 ng/ml, range 1.3-2.9 ng/ml) were significantly lower (p less than 0.001) than in patients with pernicious anemia. "
01/01/1982 - "In 20 patients with pernicious anemia the mean serum pepsinogen II level was 10.6 +/- 2.5 ng/ml, not different from normal, but significantly higher (p less than 0.001) than the level of pepsinogen I which was 5.9 +/- 4.7 ng/ml. IN 10 patients with total gastrectomy, serum pepsinogen I was 3.9 +/- 3.1 ng/ml and serum pepsinogen II was 3.2 +/- 3.1 ng/ml; both values were significantly lower (p less than 0.001) than the corresponding levels in pernicious anemia. "
01/01/1982 - "The predominance of pepsinogen I in the serum of healthy control subjects suggests that either the gastric chief cell normally releases more pepsinogen I than pepsinogen II into the circulation or that pepsinogen I has longer metabolic clearance rate than pepsinogen II. The marked decrease in serum pepsinogen I in patients with pernicious anemia is best explained by a loss of gastric chief cells due to severe atropic gastritis of te fundic glands. "
06/01/1993 - "The levels of serum pepsinogen I (PG I) and pepsinogen II (PG II) were determined by IRMA (immunoradiometric assay) and the ratio of PG I/II calculated in 37 patients with type A gastritis and concomitant pernicious anemia (PA) and in 97 with chronic gastritis (type B gastritis) among Japanese. "
Order ALL the reference details at left...

Related Drugs and Biologics

1. Pepsinogen A (Pepsinogen)
2. Gastrins
3. Biological Markers (Surrogate Marker)
4. Prostaglandins A (PGA)
5. Proteins (Proteins, Gene)
6. Antibodies
7. gastrin 17 (G 17)
8. Pepsinogens
9. Immunoglobulin G (IgG)
10. Peptide Hydrolases (Proteases)

Related Therapies and Procedures

1. Gastrectomy
2. Proximal Gastric Vagotomy
3. Gastroenterostomy
4. Roux-en-Y Anastomosis (Anastomosis, Roux en Y)
5. Aftercare (After-Treatment)

blog comments powered by Disqus
TREATMENT OPTIONS
for Gastritis,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.
  • Free Updates for 1 Year
  • All 177 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Evidence References
  • Sample PDF Report on Psoriasis >>
Price:$8.50 USD & Delivery via PDF download
updates for 1 year
Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:
Price:$45.00 USD access via web interface
1 year subscription
Request Bulk Institution License Details >>